Goodwin

Daniel Karelitz

Deals
10
Latest
Jun 2026
Most deals in
Biotech

Firm

  • Goodwin Law firm · 2026 · 10 deals
Deals by year
Daniel Karelitz: deals by year051020252026 YTD: 9 M&A2026 YTD: 1 Equity raisings102026 YTDM&AEquity raisings

Often works with

Deals

Deals dated after 30 September 2026 are still being collected.

Columns
Deals Daniel Karelitz was named on, most recent first
Jun 2026 Alloy Enterprises –Johnson ControlsAcquisitionLegal adviser to Alloy Enterprises (target)Announced–Manufacturing+2Johnson Controls acquisition of Alloy Enterprises
Jun 2026 Topaz Labs –AdobeAcquisitionLegal adviser to Topaz Labs (target)Announced–AIAdobe acquisition of Topaz Labs
May 2026 LimmaTech Biologics AG –Eli Lilly and CompanyAcquisitionLegal adviser to LimmaTech Biologics AG (target)Pending780.0BiotechEli Lilly and Company acquisition of LimmaTech Biologics AG
Apr 2026 Obsidian Therapeutics ––PlacementLegal adviser to Obsidian TherapeuticsCompleted350.0Biotech+2Obsidian Therapeutics placement
Apr 2026 Obsidian Therapeutics –Galera TherapeuticsMergerLegal adviser to Obsidian TherapeuticsCompleted413.5Biotech+2Galera Therapeutics and Obsidian Therapeutics merger
Apr 2026 Tubulis EQT Life Sciences (LSP 7 fund)Gilead SciencesAcquisitionLegal adviser to Tubulis (target)Announced3,150.0Biotech+2Gilead Sciences acquisition of Tubulis
Mar 2026 Ouro Medicines –GileadAcquisitionLegal adviser to Ouro Medicines (target)Announced1,675.0Biotech+1Gilead acquisition of Ouro Medicines
Feb 2026 Bruder Consulting & Venture Group –Dark Horse Consulting GroupAcquisitionLegal adviser to Bruder Consulting & Venture Group (target)Completed–Accounting, legal and consulting+1Dark Horse Consulting Group acquisition of Bruder Consulting & Venture Group
Feb 2026 Laysan Bio –Gannet BioChemAcquisitionLegal adviser to Gannet BioChem (acquirer)Announced–Pharma Services+2Gannet BioChem acquisition of Laysan Bio
Feb 2026 Orna Therapeutics –Eli Lilly and CompanyAcquisitionLegal adviser to Orna Therapeutics (target)Announced2,400.0Biotech+1Eli Lilly and Company acquisition of Orna Therapeutics

Deals where Daniel Karelitz is named on the firm's deal team, by the firm or the press.

Suggest a correction

A missing deal, a wrong firm, a move between firms, or two different people shown as one. A link to a public source helps.